TechMARK movers: AstraZeneca blockbuster drug approval delayed

17th Dec 2010 12:22

AstraZeneca has slumped on the back of a further delay is getting US approval for blood-thinning drug Brilinta.The US Food and Drug Administration requested additional analysis of the data from a study of the effects of Brilinta (ticagrelor) on 18,600 patients in 43 countries compared with its main rival Plavix - the second largest selling drug in the world, with global revenue of nearly $10bn last year.The trial showed that Brilinta was more effective than market leader Plavix (clopidogrel), manufactured by Sanofi-Aventis and Bristol-Myers Squibb, in preventing heart attacks, strokes and other heart-related deaths, but had a much higher number of negative outcomes in US patients.Scar reduction treatments developer Renovo is continuing its rise this week following its interim figures on Tuesday. Renovo has £51.8m in cash and the shares have risen by more than one-quarter over the week. FTSE TechMARK - RisersNXT (NTX) 3.88p +3.47%Autonomy Corporation (AU.) 1,501.00p +2.46%Kofax (KFX) 284.00p +1.70%BT Group (BT.A) 182.30p +1.62%XP Power Ltd. (DI) (XPP) 1,105.00p +1.47%Renovo Group (RNVO) 57.75p +1.32%Filtronic (FTC) 40.00p +1.27%Promethean World (PRW) 58.25p +0.87%FTSE TechMARK - FallersProStrakan Group (PSK) 86.25p -5.48%AstraZeneca (AZN) 2,984.50p -5.34%Antisoma (ASM) 6.15p -3.91%Optos (OPTS) 175.00p -3.85%Ark Therapeutics Group (AKT) 4.00p -3.61%Emblaze Ltd. (BLZ) 48.00p -3.03%Alterian (ALN) 192.00p -2.66%Oxford Instruments (OXIG) 682.00p -2.57%Psion (PON) 96.00p -2.04%Dialight (DIA) 515.00p -1.90%Vectura Group (VEC) 67.00p -1.47%